Table 4.

Outcome

	Primary immunodeficiencies (n = 20)	Idiopathic and post infectious (n = 39)	Other etiologies (n = 39)	All (n = 98)	P value
Follow-up time (months)	110 [87.2;140.5]	122.5 [83;156.2]	114 [79.5;155.5]	114 [84.5;153]	0.92
Number of visits (mean ± SD)	9.4 ± 3.7	9.4 ± 6.5	10.5 ± 5.4	9.8 ± 5.5	0.44
Admission (days/y)	0.45 [0.05;4.675]	1.4 [0.7;4.2]	1.6 [0.3;6]	1.35 [0.3;5.125]	0.4
Admission in ICU	1 (5%)	9 (23.1%)	7 (17.9%)	17 (17.4%)	0.22
Cardiovascular events	0	3 (7.7%)	3 (7.7%)	6 (6.1%)	0.44
Hemoptysis	4 (20%)	14 (35.9%)	13 (33.3%)	31 (31.6%)	0.44
Exacerbation rate (/y)	0.8 [0.525;1.475]	0.6 [0.25;1.4]	0.8 [0.3;1.5]	0.8 [0.3;1.4]	0.51
Pneumoniae	12 (60%)	19 (52.8%)	24 (61.5%)	55 (56.1%)	0.48
Chronic colonization	5 (25%)*	22 (56.4%)*	17 (43.6%)	44 (44.9%)	0.022
Aspergillus	2 (10%)	7 (17.9%)	9 (23.1%)	18 (18.4%)	0.47
Pseudomonas aeruginosa	4 (20%)§	18 (46.2%)§	11 (28.2%)	33 (33.7%)	0.05
NMT infection	1 (5%)	7 (17.9%)	6 (15.4%)	14 (14.3%)	0.39
Lung function
FEV1 variation (mL/y)	−19.82 [−48.6;−16.1]	−22.86 [−36.7;−4.1]	−28.44 [−49.2;−11.2]	−25.03 [−43.9;−8.2]	0.437
FEV1 variation (%/y)	−1.345 [− 2.5;−0.48]	−1.08 [− 1.85;0.34]	−1.5 [− 2.47;−0.15]	−1.31 [− 2.35;−0.10]	0.48
FEV1/VC variation (%/y)	−0.605 [− 1.44;0.46]	−0.3 [− 1.25;0.39]	−1.00 [− 1.75;−0.27]	−0.55 [− 1.47;0.24]	0.09
RV/TLC variation (%/y)	1.14 [0.15;2.5]	0.85 [−0.51;2.6]	1,19 [−0.44;36]	1.1 [− 0.06;2.7]	0.81
Bhalla score variation(%/y)	0.98 [0;2.5]	1 [0;2.86]	0.96 [0.52;2.77]	0.95 [0;2.74]	0.7
Deceased	2 (10%)	5 (12.8%)	4 (10.3%)	11 (11.2%)	0.95
Respiratory cause	1 (50%)	4 (80%)	3 (75%)	8 (72.7%)	0.72

ICU: Intensive Care Unit; NMT: non-tuberculous Mycobacterial infection; FEV1: Forced Expiratory Volume in 1 s; VC: Vital Capacity; RV: Residual Volume; TLC: Total Lung Capacity. Results expressed as median with interquartile range. When significant differences were reached, they are shown with a superscript note between the tested groups